Manages PPGL medically in pregnancy by initiating selective alpha‑blockers at diagnosis and adding calcium antagonists (nifedipine or amlodipine) if blood pressure control is insufficient before delivery. Triggers include: 'Pregnant patient diagnosed with PPGL,' 'Requiring blood pressure control in pregnant PPGL patient,' and 'Medical management of PPGL throughout pregnancy.'
Scanned 9/9/2026
Install to Claude Code
npx -y skills add dromlakhani/MD2SKILL --skill ppgl-pregnancy-medical-management --agent claude-codeInstalls into .claude/skills of the current project.
Are you the author of Ppgl Pregnancy Medical Management?
Add the live security badge to your README — it updates automatically with every re-scan.
[](https://www.skillsdirectory.com/skills/dromlakhani-ppgl-pregnancy-medical-management)More formats (shields.io, HTML) on the badges page.
---
name: ppgl-pregnancy-medical-management
description: Manages PPGL medically in pregnancy by initiating selective alpha‑blockers at diagnosis and adding calcium antagonists (nifedipine or amlodipine) if blood pressure control is insufficient before delivery. Triggers include: 'Pregnant patient diagnosed with PPGL,' 'Requiring blood pressure control in pregnant PPGL patient,' and 'Medical management of PPGL throughout pregnancy.'
---
# Pregnancy-Specific PPGL Medical Management
## STEP 1 — Gather Information
Confirm pregnancy status and gestational age; obtain biochemical PPGL markers (24‑hour urinary fractionated metanephrines or plasma‑free fractionated metanephrines); perform obstetric‑safe imaging (ultrasound first, MRI if needed) to localize tumor; assess maternal blood pressure, heart rate, symptoms, and fetal well‑being.
**Action:** Proceed to step 2 if PPGL is biochemically confirmed and imaging shows a lesion.
## STEP 2 — Rule In / Rule Out
Rule out pregnancy‑related hypertension (preeclampsia, gestational hypertension) by checking for proteinuria, liver enzymes, platelets, and absence of PPGL biochemical excess; if catecholamine metabolites are ≥3× upper limit, rule in PPGL.
**Action:** If PPGL ruled in, move to step 3; otherwise manage as routine hypertensive disorder of pregnancy.
## STEP 3 — Classify or Stratify
Stratify by gestational age and hypertension severity: <24 weeks → consider tumor resection if feasible; ≥24 weeks → prioritize medical control until delivery; classify BP as mild (<150/100 mmHg) or severe (≥150/100 mmHg) to guide agent intensity.
**Action:** Select medical management pathway based on stratum.
## STEP 4 — Decide
Initiate a selective α‑blocker (e.g., prazosin 0.5–1 mg at bedtime, titrate to effect); if BP remains uncontrolled, add a calcium antagonist (nifedipine ER 30–60 mg daily or amlodipine 5–10 mg daily); avoid metyrosine, ARBs, ACE‑Is, and direct renin inhibitors; use β‑blockers only for refractory tachycardia after adequate α‑blockade; consider magnesium sulfate for preeclampsia‑range hypertension; plan surgical resection in the second trimester (up to 24 weeks) only if tumor is resectable and maternal/fetal status permits.
**Action:** Implement chosen pharmacologic regimen and arrange multidisciplinary review for possible surgery.
## Clinical Guardrails / Mimics / Pitfalls
Do not start β‑blockers before α‑blockade (risk of hypertensive crisis); avoid metyrosine due to unknown fetal safety; ARBs, ACE‑Is, and direct renin inhibitors are contraindicated (fetotoxicity); limit CT and 123I‑MIBG scintigraphy unless maternal benefit clearly outweighs fetal radiation risk; monitor for orthostatic hypotension and fetal growth restriction; magnesium sulfate is reserved for preeclampsia, not routine PPGL hypertension.
## Concrete Clinical Example
A 32‑year‑old G2P1 at 18 weeks gestation presents with episodic headaches, palpitations, and BP 168/102 mmHg. Urinary fractionated metanephrines are 5× upper limit; MRI shows a 2.8 cm left adrenal lesion. No proteinuria. Start prazosin 0.5 mg nightly; after 3 days BP 148/94 mmHg, increase to 1 mg nightly; BP 138/88 mmHg achieved. Continue α‑blocker alone, plan laparoscopic adrenalectomy at 22 weeks after anesthesia and obstetric clearance.
**Source:** Clinical Practice Guideline for the Diagnosis and Management of Pheochromocytoma and Paraganglioma 2025, Japan Endocrine Society, 2025, doi:10.1507/endocrj.EJ25-0165
Is this your skill, or is something wrong with this listing? Request removal or report an issue. Author removals are honored within 72 hours.
No comments yet. Be the first to comment!